Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions

N. Franklin Adkinson; David Essayan; Rebecca Gruchalla; Helen Haggerty; Thomas Kawabata; J. David Sandler; Lawrence Updyke; Neil H. Shear; Daniel Wierda

doi:10.1067/mai.2002.122214

Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions

N. Franklin Adkinson, David Essayan, Rebecca Gruchalla, Helen Haggerty, Thomas Kawabata, J. David Sandler, Lawrence Updyke, Neil H. Shear, Daniel Wierda

Research output: Contribution to journal › Article

73 Scopus citations

Abstract

Immune-mediated drug hypersensitivity reactions (IDHR) have a significant impact on clinical practice, drug development, and public health. However, research to understand IDHR mechanisms and to develop diagnostic and predictive tests has been limited. To stimulate more research, a task force with representatives from the key stakeholders (research clinicians, regulatory scientists, and immunotoxicologists from the pharmaceutical industry) was assembled to identify critical data gaps and opportunities and to make recommendations on how to overcome some of the barriers to IDHR research and address research needs. It is hoped that this report will act as a springboard for future discussions and progress toward increased funding and development of organizational structures for IDHR research.

Original language	English (US)
Pages (from-to)	S461-S478
Journal	Journal of Allergy and Clinical Immunology
Volume	109
Issue number	3
DOIs	https://doi.org/10.1067/mai.2002.122214
State	Published - Jan 1 2002

Keywords

Adverse drug reactions
Drug allergy
Drug development
Drug hypersensitivity
Immunotoxicology

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1067/mai.2002.122214

Fingerprint Dive into the research topics of 'Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions'. Together they form a unique fingerprint.

Cite this

Adkinson, N. F., Essayan, D., Gruchalla, R., Haggerty, H., Kawabata, T., Sandler, J. D., Updyke, L., Shear, N. H., & Wierda, D. (2002). Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 109(3), S461-S478. https://doi.org/10.1067/mai.2002.122214

Task force report : Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. / Adkinson, N. Franklin; Essayan, David; Gruchalla, Rebecca; Haggerty, Helen; Kawabata, Thomas; Sandler, J. David; Updyke, Lawrence; Shear, Neil H.; Wierda, Daniel.

In: Journal of Allergy and Clinical Immunology, Vol. 109, No. 3, 01.01.2002, p. S461-S478.

Research output: Contribution to journal › Article

Adkinson, N. Franklin ; Essayan, David ; Gruchalla, Rebecca ; Haggerty, Helen ; Kawabata, Thomas ; Sandler, J. David ; Updyke, Lawrence ; Shear, Neil H. ; Wierda, Daniel. / Task force report : Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. In: Journal of Allergy and Clinical Immunology. 2002 ; Vol. 109, No. 3. pp. S461-S478.

@article{355cdcde31654a06ae2c2ac15b712bb3,

title = "Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions",

abstract = "Immune-mediated drug hypersensitivity reactions (IDHR) have a significant impact on clinical practice, drug development, and public health. However, research to understand IDHR mechanisms and to develop diagnostic and predictive tests has been limited. To stimulate more research, a task force with representatives from the key stakeholders (research clinicians, regulatory scientists, and immunotoxicologists from the pharmaceutical industry) was assembled to identify critical data gaps and opportunities and to make recommendations on how to overcome some of the barriers to IDHR research and address research needs. It is hoped that this report will act as a springboard for future discussions and progress toward increased funding and development of organizational structures for IDHR research.",

keywords = "Adverse drug reactions, Drug allergy, Drug development, Drug hypersensitivity, Immunotoxicology",

author = "Adkinson, {N. Franklin} and David Essayan and Rebecca Gruchalla and Helen Haggerty and Thomas Kawabata and Sandler, {J. David} and Lawrence Updyke and Shear, {Neil H.} and Daniel Wierda",

year = "2002",

month = jan,

day = "1",

doi = "10.1067/mai.2002.122214",

language = "English (US)",

volume = "109",

pages = "S461--S478",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Task force report

T2 - Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions

AU - Adkinson, N. Franklin

AU - Essayan, David

AU - Gruchalla, Rebecca

AU - Haggerty, Helen

AU - Kawabata, Thomas

AU - Sandler, J. David

AU - Updyke, Lawrence

AU - Shear, Neil H.

AU - Wierda, Daniel

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Immune-mediated drug hypersensitivity reactions (IDHR) have a significant impact on clinical practice, drug development, and public health. However, research to understand IDHR mechanisms and to develop diagnostic and predictive tests has been limited. To stimulate more research, a task force with representatives from the key stakeholders (research clinicians, regulatory scientists, and immunotoxicologists from the pharmaceutical industry) was assembled to identify critical data gaps and opportunities and to make recommendations on how to overcome some of the barriers to IDHR research and address research needs. It is hoped that this report will act as a springboard for future discussions and progress toward increased funding and development of organizational structures for IDHR research.

AB - Immune-mediated drug hypersensitivity reactions (IDHR) have a significant impact on clinical practice, drug development, and public health. However, research to understand IDHR mechanisms and to develop diagnostic and predictive tests has been limited. To stimulate more research, a task force with representatives from the key stakeholders (research clinicians, regulatory scientists, and immunotoxicologists from the pharmaceutical industry) was assembled to identify critical data gaps and opportunities and to make recommendations on how to overcome some of the barriers to IDHR research and address research needs. It is hoped that this report will act as a springboard for future discussions and progress toward increased funding and development of organizational structures for IDHR research.

KW - Adverse drug reactions

KW - Drug allergy

KW - Drug development

KW - Drug hypersensitivity

KW - Immunotoxicology

UR - http://www.scopus.com/inward/record.url?scp=0036128527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036128527&partnerID=8YFLogxK

U2 - 10.1067/mai.2002.122214

DO - 10.1067/mai.2002.122214

M3 - Article

C2 - 11897992

AN - SCOPUS:0036128527

VL - 109

SP - S461-S478

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -